Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme Tissue Repair - GZTR -- Ignore unavailable to you. Want to Upgrade?

To: Skeeter Bug who wrote (364)	3/10/2000 12:07:00 PM
From: KLH	Read Replies (2) \| Respond to of 405

Any thoughts why GZTR has been performing like a dog after the announcement and CC? Karl

To: Skeeter Bug who wrote (364)	3/11/2000 1:34:00 AM
From: Ron Sovak	Read Replies (2) \| Respond to of 405

Well skeeter, the whole Biotech group has been subject to profit taking. Mutual fund mangers have to sell when clients withdraw funds. BXM was downgraded since it had limited upside (due to the take over price). If you want to be part of the new company buy GZSP (at current prices) it offers the best discount. If the deal goes through BXM would be a good guaranteed up, due to the takeover price of $37. This stock has been under pressure since 1) no one understands the deal 2) short term limited upside 3)The unknown number of shares that will seek the cash payout. I think you'll get $37 a share in June for BXM(as announced). If the new company has upside and your going to hold past the takeover date then GZSP is the way to go at current prices. The key to getting $37 dollars for BXM is the number of shares management owns. They agreed to take stock for their shares. That leaves enough cash to buy about 6.7M shares (of 23M) at $37. I think you'll get $37 in June so I bought BXM this week. Selling is due to uncertainty in the deal (there is risk that it won't happen or too many shareholders will want cash) and just pressure for high performance in the short term for Biotechs.